interim marketing authorization regarding the use of the alpha-amylase enzyme in the production of brewers mash distillers mash dextrins maltose dextrose glucose glucose syrup and glucose solids dried glucose syrup available in english and french 2 pages . health canada has received a submission to permit the use of the alpha-amylase enzyme derived from a genetically modified bacillus licheniformis organism the bacillus licheniformis mol2083 pca164-le399 that carries a hybrid gene from bacillus amyloliquefaciens and bacillus licheniformis coding for this enzyme. this alpha-amylase will be used in the production of brewers mash distillers mash dextrins maltose dextrose glucose glucose syrup and glucose solids dried glucose syrup . evaluation of available data supports the safety and effectiveness of this alpha-amylase enzyme derived from the genetically modified bacillus licheniformis mol2083 pca164-le399 . the use of this alpha-amylase enzyme derived from this modified micro-organism will benefit the consumer through the availability of quality food products. it will also benefit industry through more efficient and improved manufacturing conditions. therefore it is the intention of health canada to recommend that the food and drug regulations be amended to permit the use of this alpha-amylase enzyme derived from the genetically modified micro-organism specified above in the production of brewers mash distillers mash dextrins maltose dextrose glucose glucose syrup and glucose solids dried glucose syrup at levels consistent with good manufacturing practice. as a means to improve the responsiveness of the regulatory system an interim marketing authorization ima is being issued to permit the immediate use of the alpha-amylase enzyme as indicated above while the regulatory process is undertaken to formally amend the regulations. a revision to this notification will be published at the start of the amendment process and members will be given the opportunity at that time to submit comments on this proposed measure